Peptide library
Liraglutide
Approved product
Randomized evidence
Evidence record
- Product and route
- Subcutaneous injection.
- Approval scope
- Saxenda: weight management for eligible patients.
- Mechanism
- Activates the GLP-1 receptor.
- Evidence
- Randomized trials.
- Limits
- Check other products separately.
- Safety context
- The label warns about severe gastrointestinal reactions.
A reading exercise
Give a comparison about liraglutide a simple test: finish the phrase compared with before looking at its conclusion. Is the proposed comparison with another group, with an earlier measurement, or with an expectation? Make three small columns for those possibilities and place the statement in the one it actually supports. A change from someone's starting point and a difference between groups answer different questions, even if the page uses the same word for both. Rewrite the headline with its comparison made explicit. If it becomes less sweeping, keep the more precise version as your reading note.
Questions to take away
- What belongs after compared with in the statement you are examining?
- Does the source compare groups, different times, or a result against an expectation?
- How would naming the comparison change the headline you first read?
Sources
Each date identifies a source check. It is separate from this page’s publication date.
- SAXENDA — NLM; checked